Seer, Inc. (SEER) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Seer, Inc. is a life sciences technology company focused on the Proteograph Product Suite, which utilizes proprietary engineered nanoparticle technology for deep proteomic analysis. The company is in the commercialization stage, selling instruments, consumables, and services primarily to academic and commercial research institutions. As of the reporting date, the company is classified as a smaller reporting company and non-accelerated filer.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $2.79 million | $4.21 million |
| Gross Profit | $0.98 million | $2.06 million |
| Net Loss | $(16.84) million | $(19.95) million |
| Operating Cash Flow | $(15.44) million | $(11.42) million |
| Cash & Investments | $219.5 million | N/A |
| Accumulated Deficit | $(482.8) million | N/A |
Liquidity: The company holds $47.3 million in cash and cash equivalents and $172.2 million in short-term and long-term investments. Management believes these resources are sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 34% ($1.41 million) year-over-year. Product revenue fell 27% and Service revenue dropped 55%, attributed to lower sales volumes and service utilization.
- Expense Reduction: Total operating expenses decreased by 20% ($4.55 million). Research and Development (R&D) expenses dropped 22% and Selling, General, and Administrative (SG&A) expenses fell 18%. These reductions were driven primarily by lower stock-based compensation and employee compensation costs.
- Net Loss Improvement: Net loss narrowed by 16% ($3.11 million) compared to Q1 2025, largely due to the significant reduction in operating expenses.
- Share Repurchases: The company repurchased 1.46 million shares of Class A common stock for $2.62 million during the quarter. The Board authorized an additional $25.0 million repurchase program in February 2026.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring significant operating losses and negative cash flows from operations for the foreseeable future as it invests in commercialization, R&D, and infrastructure. No specific financial guidance was provided in the text.
Key Risks and Contingencies:
- Commercialization Risk: Success depends on broad market acceptance of the Proteograph Product Suite. The company faces competition from established life sciences firms and risks related to the adoption of new proteomics technologies.
- Intellectual Property: The company relies on licensed patents from Brigham and Women's Hospital (BWH). Recent Inter Partes Review proceedings resulted in the invalidation of 6 of 11 challenged claims in a key U.S. patent, though 5 were upheld. Other patent challenges remain ongoing in Europe.
- Customer Concentration: One customer accounted for 13% of total revenue in Q1 2026. International revenue comprised 39% of total revenue.
- Supply Chain: The company relies on a single contract manufacturer (Hamilton Company) for its automation instruments.
- Tax Attributes: A Tax Benefit Preservation Plan (poison pill) was adopted in February 2026 to protect Net Operating Losses (NOLs) from ownership changes.
Investor Verification Checklist
- Verify the sustainability of the 34% revenue decline and the trajectory of the new Proteograph ONE assay and SP200 instrument adoption.
- Monitor the status of ongoing patent litigation, specifically the European nullity action against Patent EP3554681 and potential appeals regarding the U.S. PTAB decision.
- Assess the impact of the single-source dependency on Hamilton Company for instrument manufacturing.
- Review the burn rate relative to the $219.5 million cash position to confirm the 12-month liquidity runway.
- Track the execution of the share repurchase program and its impact on cash reserves.